Cooper Companies, Inc. (NASDAQ: COO)

THE COOPER COMPANIES, INC. designs, manufactures, and markets medical devices focused on vision care and women's health. The company conducts its business through subsidiaries located in the Americas, Europe, Middle East, Africa, and Asia Pacific. Its core activities include the production of soft contact lenses and a diversified portfolio of surgical devices, cryostorage solutions, contraceptive products, and fertility diagnostics and treatments. THE COOPER COMPANIES, INC. sells its products to eye care practitioners, hospitals, ambulatory surgery centers, medical offices, fertility clinics, and retail distributors worldwide.

The company generates revenue primarily from the sale of its contact lenses and women's health products. In the 3 months ended January 31, 2026, CooperVision reported net sales of $695.1 million, comprising $351.2 million from toric and multifocal lenses and $343.9 million from spherical and other lenses. Within CooperVision, toric and multifocal sales grew 10% year over year driven by MyDay and Biofinity, while spherical and other sales increased 5% due to demand for MiSight, Biofinity, and MyDay products. CooperSurgical generated net sales of $329.0 million in the same period, with $202.4 million from office and surgical offerings and $126.6 million from fertility offerings. Office and surgical revenue includes surgical devices, cryostorage for cord blood and tissue, and contraception products, which rose 2% due to higher surgical device sales. Fertility revenue encompasses diagnostics, consumables, equipment, donor gamete services, and genetic testing, increasing 6% as a result of greater demand for consumable products. These products are sold to eye care professionals, hospitals, ambulatory surgery centers, medical offices, fertility clinics, and patients seeking assisted reproductive care.

The company operates through the following segments.

• CooperVision: This segment designs, manufactures, and distributes soft contact lenses including spherical, toric, multifocal, and myopia management lenses made from silicone hydrogel materials such as Aquaform and ActivControl, with product families like clariti, MyDay, MyDay Energys, Biofinity, Avaira Vitality, and the FDA approved MiSight 1 day lens aimed at slowing myopia progression in children aged 8 to 12.

• CooperSurgical: This segment provides a diversified portfolio of products and services for fertility and women's health care, encompassing surgical devices for gynecologic procedures, cryostorage solutions for cord blood and tissue, contraceptive offerings such as Paragard, and fertility solutions that include diagnostics, consumables, equipment, donor gamete services, and genetic testing to support in vitro fertilization and assisted reproductive technologies.

In the global contact lens market, THE COOPER COMPANIES, INC. competes with major players such as Johnson & Johnson Vision, Alcon, and Bausch + Lomb, maintaining a strong position through its proprietary silicone hydrogel technologies and innovative myopia management portfolio. The company's advantages include its Aquaform and ActivControl lens materials, the FDA approved MiSight 1 day lens, and a broad distribution network that reaches eye care professionals in over 100 countries. In the fertility and women's health sector, CooperSurgical faces competition from companies like Hologic and CooperSurgical's integrated suite of surgical tools, cryostorage, contraception, and fertility diagnostics provides a differentiated offering that appeals to hospitals, clinics, and physicians seeking comprehensive reproductive health solutions.

THE COOPER COMPANIES, INC.'s customer base comprises optometrists and ophthalmologists who prescribe its contact lenses to end users, as well as retail distributors and pharmacies that dispense the lenses to consumers. CooperSurgical serves hospitals, ambulatory surgery centers, medical offices, obstetricians and gynecologists, fertility clinics, and patients undergoing assisted reproductive treatments such as in vitro fertilization and intrauterine insemination.